Clifford A. Hudis, MD, Attending Physician, Memorial Sloan-Kettering Cancer Center, discusses his optimism surrounding immunotherapy for cancer care.
Clifford A. Hudis, MD, ASCO President-Elect, Chief, Breast Cancer Medicine Service, Attending Physician, Memorial Sloan-Kettering Cancer Center, discusses his optimism surrounding immunotherapy for cancer care.
Hudis says that following the 2012 ASCO Annual Meeting, this is now the second year of active manipulation of the immune system as a way of treating refractory diseases like melanoma. Now, there is substantial evidence that combinations of drugs activate the immune system.
At the 2013 ASCO meeting, new immunotherapy data were presented in metastatic melanoma. Hudis is optimistic because of the narrow application in a difficult-to-treat disease and because the results indicate the ability to treat a variety of metastatic solid tumors.
<<<
Brain Cancer Awareness Month: Challenges and Innovations in Treatment
May 13th 2024In an interview with Targeted Oncology for Brain Cancer Awareness Month, Theodore Schwartz, MD, discussed the challenges of targeting brain tumors, emerging therapies, and strategies to overcome the blood-brain barrier.
Read More